[go: up one dir, main page]

PA8651501A1 - Derivados de sulfonilbencimidazol - Google Patents

Derivados de sulfonilbencimidazol

Info

Publication number
PA8651501A1
PA8651501A1 PA20058651501A PA8651501A PA8651501A1 PA 8651501 A1 PA8651501 A1 PA 8651501A1 PA 20058651501 A PA20058651501 A PA 20058651501A PA 8651501 A PA8651501 A PA 8651501A PA 8651501 A1 PA8651501 A1 PA 8651501A1
Authority
PA
Panama
Prior art keywords
birthday
dolorium
pain
disease
compounds
Prior art date
Application number
PA20058651501A
Other languages
English (en)
Inventor
Miyako Matsumizu
Kana- Kon
Akiko Shima
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PA8651501A1 publication Critical patent/PA8651501A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS DE FORMULA (I): O A UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LOS MISMOS, EN LA QUE CADA UNO DE A, B, R1, R2, Y R3 ES COMO SE DESCRIBE EN ESTE DOCUMENTO, Y A COMPOSICIONES QUE CONTIENEN TALES COMPUESTOS, Y AL USO DE TALES COMPUESTOS EN ELTRATAMIENTO DE UNA AFECCION MEDIADA POR LA ACTIVIDAD DEL RECEPTOR CB2 TAL COMO, SIN LIMITACION , DOLOR INFLAMATORIO, DOLOR NOCICEPTIVO. DOLOR NEUROPATICO, FIBROMIALGIA, DOLOR CRONICO EN LA PARTE INFERIOR DE LA ESPALDA, DOLOR VISCERAL, ISQUEMIA CEREBRAL AGUDO, NEURALGIA POST HERPETICA, NEUROPATIAS, NEURALGIA DIABETICA, NEUROPATIA RELACIONADA CON VIH, LESION NERVIOSA, DOLOR ARTRITICO REUMATOIDE, DOLOR OSTEORTRITICO, DOLOR POR CANCER, DOLOR DENTAL, FIBROMIALGIA, NEURITIS, CIATICA, INFLAMACION, ENFERMEDAD NEURODEGENERATIVA, TOS, BRONCOCONSTRICCION, SINDROME DEL INTESTINO IRRITABLE (IBS), ENFERMEDAD DEL INTESTINO (IBD), COLITIS, ISQUEMIA CEREBROVASCULAR, EMESIS TAL COMO EMESIS INDUCIDA POR LA QUIMIOTERAPIA DEL CANCER, ARTRITIS REUMATOIDE, ASMA, ENFERMEDAD DE CROHN, COLITIS ULCEROSO, ASMA, DERMATITIS, RINITIS ALERGICA ESTACIONAL, GERD, ESTREÑIMIENTO, DIARREA, TRASTORNO GASTROINTESTINAL FUNCIONAL, SINDROME DEL INTESTINO IRRITABLE, LINFOMA CUTANEO DE CELULAS T, ESCLEROSIS MULTIPLE, OSTEOARTRITIS, PSORIASIS, LUPUS ERITEMATOSO SISTEMICO, DIABETES, GLAUCOMA, OSTEOPOROSIS GLOMERULONEFRITIS, ISQUEMIA RENAL, NEFRITIS, HEPATITIS, APOPLEJA CEREBRAL, VASCULITIS, INFARTO DE MIOCARDIO, ISQUEMIA CEREBRAL, OBSTRUCCIÓN REVERSIBLE DE LAS VIAS RESPIRATORIAS, SINDROME DE ENFERMEDAD RESPIRATORIA EN ADULTOS, COPD, BRONQUITIS Y ALVEOLITIS FIBROSANTE CRIPTOGENICA.
PA20058651501A 2004-11-02 2005-11-02 Derivados de sulfonilbencimidazol PA8651501A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62457804P 2004-11-02 2004-11-02
US69635805P 2005-06-30 2005-06-30

Publications (1)

Publication Number Publication Date
PA8651501A1 true PA8651501A1 (es) 2006-06-02

Family

ID=35915103

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20058651501A PA8651501A1 (es) 2004-11-02 2005-11-02 Derivados de sulfonilbencimidazol

Country Status (18)

Country Link
US (1) US7598393B2 (es)
EP (1) EP1809607B1 (es)
JP (1) JP2008518905A (es)
AR (1) AR053774A1 (es)
AT (1) ATE417830T1 (es)
BR (1) BRPI0517925A (es)
CA (1) CA2586179C (es)
DE (1) DE602005011844D1 (es)
DO (1) DOP2005000221A (es)
ES (1) ES2318556T3 (es)
GT (1) GT200500309A (es)
MX (1) MX2007005290A (es)
NL (1) NL1030324C2 (es)
PA (1) PA8651501A1 (es)
PE (1) PE20060937A1 (es)
TW (1) TW200621724A (es)
UY (1) UY29184A1 (es)
WO (1) WO2006048754A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE241351T1 (de) 1996-07-24 2003-06-15 Warner Lambert Co Isobutylgaba und dessen derivate zur schmerzbehandlung
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
KR101269869B1 (ko) * 2004-09-24 2013-06-07 네오메드 인스티튜트 벤즈이미다졸 유도체, 그를 함유하는 조성물, 그의 제조방법 및 그의 용도
DE602006019119D1 (de) * 2005-09-30 2011-02-03 Glaxo Group Ltd Verbindungen mit aktivität am m1-rezeptor und ihre verwendung in der medizin
EP1937670A1 (en) * 2005-09-30 2008-07-02 Glaxo Group Limited Benzimidazolones which have activity at m1 receptor
WO2007036718A2 (en) * 2005-09-30 2007-04-05 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
DE602007009807D1 (de) 2006-03-06 2010-11-25 Raqualia Pharma Inc Sulfonylbenzimidazolderivate
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
BRPI0714199A2 (pt) * 2006-07-04 2012-12-25 Janssen Pharmaceutica Nv agonistas de canabinàide de benzimidazol que transportam um grupo heterocÍclico substituÍdo
US20090325936A1 (en) * 2006-12-20 2009-12-31 Bilodeau Mark T Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
ES2548764T3 (es) * 2007-03-30 2015-10-20 Janssen Pharmaceutica N.V. Agonistas de cannabinoides de bencimidazol
WO2009036297A1 (en) * 2007-09-14 2009-03-19 The Trustees Of The University Of Pennsylvania Novel compounds for treatment of malignant tumors
GB0718415D0 (en) * 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds
ES2574130T3 (es) * 2007-12-17 2016-06-15 Janssen Pharmaceutica, N.V. Bencimidazoles sustituidos con fluoroalquilo como agonistas cannabinoides
BRPI1007202A2 (pt) * 2009-01-22 2016-02-23 Raqualia Pharma Inc composto de fórmula (i), composição farmacêutica, método para tratamento de condição mediada pela atividade do receptor cb2 em um indivíduo mamífero e uso de composto de fórmula (i)
EP2433124B1 (en) * 2009-05-19 2017-03-01 Vivia Biotech S.L. Methods for providing personalized medicine tests ex vivo for hematological neoplasms
US20110086853A1 (en) * 2009-10-08 2011-04-14 William Brown Therapeutic Compounds
AU2010314891A1 (en) 2009-11-06 2012-06-07 Vanderbilt University Aryl and heteroaryl sulfones as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
RU2414899C1 (ru) * 2009-12-29 2011-03-27 Аверин Константин Михайлович Средства для лечения рассеянного склероза
CN105566182B (zh) * 2016-02-24 2018-02-13 苏州天马精细化学品股份有限公司 一种2‑氨基‑4‑（乙磺酰基）苯酚的合成方法
GB201811169D0 (en) 2018-07-06 2018-08-29 Kancera Ab New compounds
US10569189B1 (en) * 2019-05-17 2020-02-25 NextLeaf Solutions Ltd. Method for acetylation of cannabinoids
WO2022128050A1 (en) 2020-12-14 2022-06-23 Symrise Ag Medicament for fighting inflammation and pain

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1481049A (fr) * 1965-11-25 1967-05-19 France Ministre Des Armees Nouveaux dialkylaminoalkyl-1 p-alkoxyphényl alkyl-2 benzimidazoles 5-substitués
GB1198633A (en) 1967-11-24 1970-07-15 Ilford Ltd Phenyl-Sulphonated Benzimidazoles
US4177057A (en) * 1977-10-25 1979-12-04 United States Borax & Chemical Corporation Herbicidal benzimidazoles
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
DE19507913C2 (de) 1995-03-07 1998-04-16 Agfa Gevaert Ag Farbfotografisches Silberhalogenidmaterial
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO1997024334A1 (en) * 1995-12-28 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
FR2751649B1 (fr) 1996-07-26 1998-08-28 Adir Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
JP2002502844A (ja) * 1998-02-03 2002-01-29 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト ５員複素環縮合ベンゾ誘導体、その調製及び医薬品としてのそれらの使用
CA2382789A1 (en) 1999-08-27 2001-03-08 Sugen, Inc. Phosphate mimics and methods of treatment using phosphatase inhibitors
AU2001236605A1 (en) 2000-02-01 2001-08-14 Cor Therapeutics, Inc. Indole and benzimidazole inhibitors of factor xa
WO2002046168A1 (en) 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic benzimidazole compounds
TW593278B (en) 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
SE0101387D0 (sv) * 2001-04-20 2001-04-20 Astrazeneca Ab Novel compounds
US6815456B2 (en) 2001-04-20 2004-11-09 Wyeth Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
SE0203070D0 (en) * 2002-10-16 2002-10-16 Astrazeneca Ab Novel compounds
JP2007521296A (ja) 2003-07-01 2007-08-02 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧の治療のための眼科用組成物
SE0302572D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302571D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EP1805147B1 (en) 2004-09-30 2014-08-13 Janssen Pharmaceutica NV Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms)
CN101133036B (zh) 2004-09-30 2010-10-13 詹森药业有限公司 可用作选择性雄激素受体调节剂(sarms)的新苯并咪唑衍生物

Also Published As

Publication number Publication date
DOP2005000221A (es) 2006-05-15
JP2008518905A (ja) 2008-06-05
MX2007005290A (es) 2007-07-09
EP1809607B1 (en) 2008-12-17
NL1030324A1 (nl) 2006-05-03
CA2586179C (en) 2011-02-08
PE20060937A1 (es) 2006-10-19
AR053774A1 (es) 2007-05-23
EP1809607A1 (en) 2007-07-25
US7598393B2 (en) 2009-10-06
US20060094750A1 (en) 2006-05-04
GT200500309A (es) 2006-09-11
ES2318556T3 (es) 2009-05-01
UY29184A1 (es) 2006-06-30
DE602005011844D1 (de) 2009-01-29
CA2586179A1 (en) 2006-05-11
WO2006048754A1 (en) 2006-05-11
TW200621724A (en) 2006-07-01
NL1030324C2 (nl) 2006-11-27
BRPI0517925A (pt) 2008-10-21
ATE417830T1 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
PA8651501A1 (es) Derivados de sulfonilbencimidazol
ATE484497T1 (de) Sulfonylbenzimidazolderivate
US20220306649A1 (en) Chemical compounds as inhibitors of interleukin-1 activity
ES2439042T3 (es) Derivados de 5,6,7,8-tetrahidroimidazo[1,2-a]pirazina como moduladores de P2X7
HRP20210252T1 (hr) Heterociklički amidi kao inhibitori kinaze
ES2618057T3 (es) Pirimidinas 5,6-sustituidas inhibidoras del VIH
CL2003002765A1 (es) Compuestos derivados de 3-[3-,5-dioxo-4,5-dihidro-3h-[1,2,4]triazin-2-il]benzamida sustituidos, composicion farmaceutica y uso del compuesto en el tratamiento de una enfermedad mediada por il-1 en un mamifero.
ES2644606T3 (es) Compuestos bicíclicos de fenil amino pirimidina y usos de los mismos
US20180022752A1 (en) Fused-ring compounds, pharmaceutical composition and uses thereof
HRP20191364T1 (hr) Sik-inhibitori tipa heteroarila
SV2008002307A (es) Derivados de 3-fenil-pirazol como moduladores del receptor 5-ht2a de la serotonina utiles para el tratamiento de trastornos relacionados con este ref. 92.sv1.reg
CL2012000981A1 (es) Compuestos derivados de 5-etinil-2-[(3-fenil-1h-pirazolo[3.4-d]pirimidin-1-il)metil]quinazolin-4(3h)-ona, inhibidores de fosfoinositida 3-quinasa compuestos intermediarios; sin accion farmacologica; composicion farmaceutica; utiles en el tratamiento de epoc, asma fibrosis quistica y pulmonar, sarcoidosis, entre otras.
ES2861927T3 (es) N-(6-((2R,3S)-3,4-Dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina
AR054084A1 (es) Derivados de indolcarboxamida y composiciones farmaceuticas que los contienen
EA201170374A1 (ru) Производные замещенных трициклических кислот в качестве агонистов рецептора s1p1, применимые при лечении аутоиммунных и воспалительных заболеваний
ES3014851T3 (en) Spiro derivatives of alpha-d-galactopyranosides
WO2011006914A3 (en) Antagonists, uses & methods for partially inhibiting tnfr1
EA200970852A1 (ru) Производные пиразоло[3,4-в]пиридина в качестве ингибиторов фосфодиэстеразы
PA8636901A1 (es) Derivados de acido carboxilico de bencimidazolona
CR20220291A (es) Derivados de furoindazol
AR074354A1 (es) Alquilciclohexileteres de dihidrotetraazabenzoazulenos, procesos de preparacion y composiciones farmaceuticas que los contienen
ES2328654B1 (es) Compuestos de indolsufonamida sustituidos, su preparacion y uso como medicamentos.
CO6450684A2 (es) Derivado de amida
AR073307A1 (es) Compuestos para el tratamiento de trastornos inflamatorios
CA3255264A1 (en) COMPOUNDS, COMPOSITIONS AND PROCESSES